// App-Quantinova.ai

229 : Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study.

Researchers

Presenter

  • Josep Tabernero

Principal Investigators

  • Kohei Shitara

  • Aziz Zaanan

  • Toshihiko Doi

  • Sylvie Lorenzen

  • Eric Van Cutsem

  • Lorenzo Fornaro

  • Daniel V.T. Catenacci

  • Ronan Fougeray

  • Shanti Ricardo Moreno Vera

  • Pablo Azcue

  • Hendrik-Tobias Arkenau

  • MARIA ALSINA

  • David H. Ilson

Medical Centers

  • Vall dHebron University Hospital Institute of Oncology, Barcelona, Spain

  • National Cancer Center, EPOC, Chiba, Japan

  • Department of Medical Oncology, Saint Antoine Hospital, UPMC University Paris 06, Paris, France

  • National Cancer Center Hospital, Tokyo, Japan

  • Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Gastrointestinal Disorders, University of Chicago Medical Center, Chicago, IL

  • Centre of EXcellence Methodology and Valorization of Data (CentEX MVD), Institut de Recherches Internationales Servier, Suresnes, France

  • Global Medical Affairs Oncology, Servier, Suresnes, France

  • Global Medical and Patient Affairs, Les Laboratoires Servier SAS, Suresnes, France

  • Sarah Cannon Research Institute, London, United Kingdom

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Spain

  • Japan

  • France

  • Germany

  • Belgium

  • Italy

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Tipiracil and trifluridine

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT02500043

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved